Insider Purchases: Inside the Buy

Tag: Science Stocks

Cartoon illustration of Illumina headquarters glowing under a DNA-shaped light beam, with a stock chart climbing in the background and two executives holding shopping bags labeled

🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!

After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?

Read entire article

Tags: Biotech Humor, Biotech Investing, CEO Buys, CEO insider buying, CEOBuyIn, CEOConfidence, CFO Bought Shares, CFO Insider Buying, Contrarian, contrarian investing, Contrarian Play, Contrarian Stocks, ContrarianPlays, DNA Stocks, Funanc1al, Funanc1al for Investors, Funanc1al Investing, Funanc1alInvesting, Future Health Tech, Genomics, Growth Stocks, Illumina, ILMN, ILMN Stock, Innovation Investing, Insider Buys, Science Stocks, Sequencing Stocks, Share buybacks, Turnaround Stocks
Cartoon of Avantor directors in lab coats pouring cash into beakers, with a new CEO stirring the mix like a scientist plotting value creation.

Avantor: A New CEO, New Numbers, and Insiders Keep Buying 💊🔬

Avantor (AVTR) just added a seasoned CEO, posted solid cash flow despite flat sales, and insiders keep buying big. Is this lab supplier quietly building shareholder value?

Read entire article

Tags: Avantor Stock, AVTR, Biopharma Supply Chain, Biotech Supply Chain, Biotech Support Industry, CEO Transition, CEO Transition Stocks, Change in Management, Cost Reduction Plan, Debt Reduction, Emmanuel Ligner, Funanc1al for Investors, Funanc1al Humor, Funanc1al Insider Series, Funanc1al Investing, Funanc1al Stocks to Watch, Funanc1al Turnaround Plays, Funanc1alEdge, Insider Buys, Lab Economy, Life Sciences Stocks, Science Stocks, Stock Market Humor, value investing, Value Trap or Comeback, Value Trap or Value Play